Immunic (NASDAQ:IMUX) Upgraded by LADENBURG THALM/SH SH to Strong-Buy Rating

LADENBURG THALM/SH SH upgraded shares of Immunic (NASDAQ:IMUX) to a strong-buy rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

Several other equities research analysts have also issued reports on the company. Lifesci Capital raised Immunic to a “strong-buy” rating in a research report on Monday, May 4th. HC Wainwright reissued a “buy” rating and set a $22.00 target price (up from $5.00) on shares of Immunic in a report on Thursday, April 30th. Stifel Nicolaus set a $25.00 price target on shares of Immunic and gave the stock a “buy” rating in a research report on Thursday, April 16th. Roth Capital reaffirmed a “buy” rating and set a $19.00 price objective on shares of Immunic in a research report on Thursday, May 14th. Finally, Wolfe Research assumed coverage on shares of Immunic in a report on Friday, May 22nd. They issued an “outperform” rating on the stock. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $47.57.

Immunic Trading Down 2.2%

Shares of NASDAQ:IMUX opened at $13.05 on Wednesday. The firm has a market cap of $177.74 million, a PE ratio of -2.34 and a beta of 1.37. The company has a fifty day simple moving average of $14.24 and a 200 day simple moving average of $11.41. Immunic has a 12-month low of $5.06 and a 12-month high of $15.84.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.37). As a group, equities research analysts forecast that Immunic will post -4.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in IMUX. Nantahala Capital Management LLC bought a new position in shares of Immunic in the fourth quarter worth $2,337,000. Millennium Management LLC raised its stake in shares of Immunic by 544.6% during the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after purchasing an additional 2,888,829 shares in the last quarter. Avidity Partners Management LP raised its stake in shares of Immunic by 42.6% during the first quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock valued at $7,436,000 after purchasing an additional 2,000,000 shares in the last quarter. Laurion Capital Management LP lifted its holdings in Immunic by 106.3% in the fourth quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock worth $2,072,000 after purchasing an additional 2,000,000 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Immunic in the first quarter worth about $1,020,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.